U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932068) titled 'Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma' on April 10.
Brief Summary: This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Study Start Date: March 26
Study Type: INTERVENTIONAL
Condition:
HER2 Negative
Low PD-L1 Expressing
Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Intervention:
DRUG: Iparomlimab and Tuvonralimab (QL1706)
5 mg...